Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Understanding brain hemisphere organization by leveraging individual differences (HEMIVAR)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Germany,Netherlands
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-11-01
End date: 2026-10-31
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 2
Project status: SIGNED

Many human-defining mental capacities recruit an extensive network of brain regions in both hemispheres, yet are dominantly controlled by one side. For example, language activates both halves of the brain, but language impairments are more severe, likely and longer-lasting when that function’s dominant hemisphere is damaged. In spite of being such an important feature of the human brain, hemisphere organization is commonly studied in a fragmented way. Theories about the benefits of hemisphere organization are incomplete, either focusing solely on the dominant side or non-dominant side. Another issue hindering progress on understanding hemisphere organization is that individual differences in hemisphere specialization are ignored, despite being massive. Combined, this led to opposing philosophies for promoting cognitive recovery after one-sided brain damage and one-size-fits-all therapies. HEMIVAR will help resolve these issues through an original integration of advanced neuroscience techniques (MRI and TMS) and sophisticated network-analysis frameworks, that will allow to study hemisphere organization in the intact and disrupted brain holistically. A major conceptual and methodological innovation is the attention to individual variability in hemisphere organization. My project will deliver a novel empirically-validated theory that jointly explains the biological roles of the dominant and non-dominant hemisphere (Objective 1) and will clarify how individual hemisphere dominance interacts with between-hemisphere connectivity (Objective 2). The project's results will constitute a significant advancement of our understanding of the human brain and will generate widely-applicable methodological recommendations for future studies. On top of that, they will serve as a stepping stone for clinical research on integrating hemisphere specialization into (patient-tailored) brain rehabilitation, in line with the EU research policy aim to promote personalized medicine.

Keywords: hemisphere specialization,tms,fmri,corpus callosum,brain networks,functional connectivity
Discovery of efficient Enzyme-like Metal Organic frameworks to activate biomethane at low temperature (DEMO)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Spain,Slovenia,France,Norway,Italy,United Kingdom,Netherlands
Call: MSCA Doctoral Networks 2022 (HORIZON-MSCA-2022-DN-01, 2022)
Start date: 2023-09-01
End date: 2027-08-31
Duration (months): 48.0
Total project cost (EUR): 3248503.2
EU funding (EUR): 3248503.2
Participants: 14
Project status: SIGNED

The main objective in DEMO is to provide high-level hands-on, computational and transferable skill training to 13 Doctoral Candidates (DC) through a Joint Doctorate Program and to create a new generation of experts in hybrid catalysis. DEMO uses light (C1-C4) alkanes as example to study the conversion of a sustainable molecule (biomethane) into a relevant chemical in industry (methanol). This project combines 9 world-class research groups, experts in chemical engineering, organic chemistry, catalysis, modelling and spectroscopy from 7 countries. The 9 partners in academic (3), research centre (3), SME (2) and industrial (1) fields will provide recruited DCs with unique perspectives, preparing DCs for their personal career in research with specific skillsets. DEMO will integrate machine learning, organic chemistry, ab initio modelling, high-throughput and reactor engineering and in situ spectroscopy to discover enzyme-like species in Metal Organic Frameworks (MOFs). Specifically, DEMO will follow an interconnected strategy to discover optimal catalyst candidates: a) virtually generate a dataset with active species in MOFs and screen via Machine Learning; b) test the dataset value of a large sample dataset via experimental high-throughput engineering and modelling; c) understand testing outputs through in situ spectroscopy, titration kinetics and modelling; d) optimise protocols for synthetic materials towards biological analogies and engineer reaction conditions to search solvation phenomena. This way, DEMO expects to have a broad impact on the scientific community, EU industry and society by providing high-quality training in hybrid catalysis.

Keywords: machine learning,solid catalysis,mofs,enzymatic catalysis
Development of a toolbox to improve preparedness strategies on surveillance in human-animal interface and countermeasures to reduce recurrent Ebola impacts (Ebola PREP-TBOX)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Global Health EDCTP3
Action type: Research and Innovation actions
Partnership: EDCTP3 (JU-JTI)
Countries involved: Congo,Congo, The Democratic Republic of the,Uganda,France,Spain,Germany
Call: Research to rapidly evaluate interventions on Ebola outbreaks in sub-Saharan Africa (HORIZON-JU-GH-EDCTP3-2023-01, 2023)
Start date: 2024-10-01
End date: 2027-09-30
Duration (months): 36.0
Total project cost (EUR): 2999868.67
EU funding (EUR): 2999868.67
Participants: 9
Project status: SIGNED

The recent outbreak of Ebola virus (EBOV), in particular the EBOV Sudan strain, is a major cause for concern as there are currently no available vaccines and treatments for this fatal disease. Moreover, surveillance measures are suboptimal and the social response to viral outbreaks hindered by limited acceptance of countermeasures. The Ebola PREP-TBOX consortium aims to make significant strides in developing essential tools and strategies for effective surveillance response, and control of Ebola outbreaks, fostering a safer and resilient future. Our objective is to build a toolbox permitting earliest Ebola outbreak containment. A spatiotemporal model utilizing environmental, animal reservoir, socioeconomic and human movement data will be developed enabling prediction of future outbreaks. The sensitivity of current diagnostics will be improved through innovative viral capture techniques. EBOV exposure and immune response will be tested from human-animal interface samples from the Republic of Congo (RoC), Democratic Republic of Congo (DRC) and Uganda. New treatments for the EBOV Sudan strain will be developed by testing for broad-spectrum activity of the EBOV anti-Zaire Equine polyclonal antibody. Further, development of mosaic antigens, composed of several filovirus strains (incl. EBOV), will create new tools for broad-spectrum vaccine and therapeutic development. Conductance of knowledge, attitude and practice (KAP) studies, gap analysis and targeted trainings in RoC, DRC and Uganda will improve population acceptance for future EBOV outbreak interventions. The training of African researchers by the consortium will increase local skills and competences. Ebola PREP-TBOX is an interdisciplinary and complementary consortium including partners from the Congo Basin (FCRM-RoC, INRB-RDC, UVRI-IAVI-Uganda), Prof. JJ Muyembé (Ebola discoverer 1976) and partners from Europe (Fabentech and Bacfly/CNRS-France, IMAS12-Spain) and the support of G Kobinger (GNL,US).

Keywords: viral hemorrhagic diseases,ebola,new multivalent therapies,multivalent vaccine candidate,polyclonal antibodies,ultrasensitive diagnostics,risk assessment modelling,kap study
Intensified tuberculosis treatment to reduce the high mortality of tuberculous meningitis in HIV-infected and uninfected patients (INTENSE-TBM-2)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Global Health EDCTP3
Action type: Research and Innovation actions
Partnership: EDCTP3 (JU-JTI)
Countries involved: France,Madagascar,South Africa,Spain,Côte d'Ivoire,Switzerland
Call: Funding to successfully finalise EDCTP2-funded clinical trials that were negatively impacted by the COVID-19 pandemic (HORIZON-JU-GH-EDCTP3-2023-01, 2023)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 2497565.0
EU funding (EUR): 2497565.0
Participants: 10
Project status: SIGNED

Tuberculosis (TB) remains a global health problem. The most lethal and disabling form of TB is tuberculous meningitis (TBM), with an estimated 100,000 new cases occurring per year. In sub-Saharan Africa, TBM mortality reaches 40% in HIV negative patients and up to 70% in HIV co-infected patients. Since decades, TBM treatment is based on a regimen used against pulmonary TB, which probably results in suboptimal drug levels in the cerebrospinal fluid (CSF). The main objective of INTENSE-TBM is to reduce the mortality and neurological complications of TBM in adults with or without HIV co-infection in sub-Saharan Africa (SSA). This is investigated via a multicentre randomised multicentre Phase III clinical trial involving 768 patients in four SSA countries to evaluate the efficacy of an intensified TB treatment regimen during the first two months of TB treatment, including high-dose rifampicin and linezolid (repurposed drug), with the addition of aspirin (not as yet authorized for TBM). This intensified TB treatment is expected to reduce mortality by at least 30% for each of the interventions and minimize neurological sequalae. The INTENSE-TBM trial is the largest ongoing trial in the field of TBM worldwide. If superiority of this experimental arm is demonstrated in terms of reduced mortality, it will become the first Phase III study to demonstrate survival benefit from intensified TBM treatment. As per the expected outcomes of this EDCTP-3 call, INTENSE-TBM-2, as the continuation of INTENSE-TBM, a clinical trial funded by EDCTP2 and whose activities were disrupted during the COVID-19 pandemic, aims at concluding the ongoing activities of the EDCTP-2 project. It also aims at complying with ethical issues, such as fully validating the willingness of trial participants to take part in the clinical investigations.

Keywords: tuberculous meningitis
Automated, miniaturized and accelerated drug discovery: AMADEUS (AMADEUS)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Products and Processes Engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: Czechia
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 3409401.0
EU funding (EUR): 3409401.0
Participants: 1
Project status: SIGNED

The mantra ‘Automation + Miniaturization = Acceleration’ is successfully applied in many research areas and technologies, but not in synthetic chemistry, which is largely believed to be not automatable. However, with the potential to accelerate discoveries while flattening costs, increase safety, streamline data generation, enhance reproducibility, and lower the environmental footprint, automation and miniaturization are two promising approaches to synthesis and are worthwhile to invest in. I will engineer and validate a comprehensive, technology platform, AMADEUS (Automated, MiniAturizeD, and acceleratEd drUg diScovery), which is able to synthesize in a fully autonomous manner thousands of small molecules per day in nano- or picolitre volumes, based on hundreds of chemistries, efficiently screened and optimized for properties using artificial intelligence. The AMADEUS process will be achieved by interfacing four different modules: a synthetic part based on acoustic droplet ejection technology, coupled with a UPLC MS QC and purification module, and a flexible mounted screening unit. A machine learning module will retrieve and process all relevant synthesis, QC, and screening ‘real-time’ data and automatically guide the iterative optimization cycle. AMADEUS will be showcased with several medicinal chemistry, catalysis, and organic chemistry projects. With my project, I want to challenge the early drug discovery process, which for over 50 years in pharma companies around the world has (almost uniformly) been pursued and comprises two blocks, 1) a high throughput screen relying on millions of curated and stored compounds and 2) the subsequent hit-to-lead optimization phase often called the ‘design, make, test cycle’. AMADEUS will contribute to the accelerated discovery of drugs for unmet medical needs and ultimately reduce drug costs for patients. AMADEUS is a highly sustainable synthesis platform. AMADEUS will help democratize drug discovery.

Keywords: autonomous drug discovery technology platform nano synthesis miniaturized organic chemistry acoustic droplet ejection machine learning evolutionary algorithm redesign dmta accelerate early drug discovery chiral catalyst optimization personalized medicine p53 y220c covalent modifier rna targeting by small molecules immuno oncology pd l1 degrader
Ion-ion COllisioN Electron Spectroscopy (ICONES)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: France
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-02-01
End date: 2028-01-31
Duration (months): 24.0
Total project cost (EUR): 226420.56
EU funding (EUR): 226420.56
Participants: 1
Project status: SIGNED

This project proposes the development of an innovative electron spectrometer to pioneer Ion-ion COllisioN Electron Spectroscopy (ICONES). Traditionally, electron spectroscopy has provided critical insights into ion-atom/molecule collisions, offering an in-depth understanding of various quantum processes such as electron capture, ionization, and excitation. However, its application to ion-ion collisions, where both collision partners are ions, is a new frontier. This research represents a significant leap beyond the current state-of-the-art, extending the use of electron spectroscopy in ion-ion collisions. The project methodology includes simulations using SIMION, assembling a portable setup with integrated electronics and data acquisition system for independent testing, and conducting proof-of-principle tests under realistic experimental conditions. ICONES will be finally integrated in the FISIC platform, which is currently being tested at the Institute of NanoSciences of Paris (INSP), CNRS. FISIC is designed to study ion-ion collisions into the hitherto unexplored intermediate energy regime, where energy deposition reaches its maximum. By leveraging recent advancements in accelerator-based technology, this project aims to open new experimental pathways, providing benchmark data for theoretical models and significantly expanding our knowledge of the complex quantum dynamics of N-body systems, thus offering detailed insights into electron correlations, the roles of screening and anti-screening in multiple mechanisms as well as multi-electron processes. The knowledge gained from this project will have broad implications across multiple fields, including astrophysics, fusion research, and ion-beam cancer therapy. Additionally, the project’s outcomes are expected to drive technological innovation by developing new spectrometers capable of high-precision measurements under extremely low-rate conditions, thus setting new standards in atomic physics research.

Keywords: ion ion collisions,electron spectroscopy,quantum dynamics,n body systems,simion
NGI International Collaboration – Transatlantic Fellowship Programme (NGI Enrichers)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Digital
Destination: A human-centred and ethical development of digital and industrial technologies
Action type: Coordination and support actions
Countries involved: France,Italy,Portugal,Canada,United States,Ukraine,United Kingdom,Switzerland
Call: NGI International Collaboration - Transatlantic fellowship programme (CSA) (HORIZON-CL4-2021-HUMAN-01, 2021)
Start date: 2022-09-01
End date: 2025-08-31
Duration (months): 36.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 13
Project status: SIGNED

NGI Enrichers aims to be the European gateway for Internet innovators to both the US and Canada. An agile and flexible fellowship programme will provide financial support to Internet innovators from European and Horizon Europe associated countries to travel to the US or to Canada and collaborate with their counterparts on NGI (Next generation Internet)-related topics, such as on trust and data sovereignty, internet architecture renovation and decentralised technologies and solutions. Three open calls will be organised and 70 to 90 EU Internet researchers and innovators will be selected for 3 to 6 months fellowships (travel and monthly allowance), and be hosted by world class US and Canadian universities, research centers, or cutting-edge Internet private sector organisations to jointly develop innovative solutions and services in line with EU values and policy priorities. A community platform will support knowledge sharing and help establish long-term collaborations on NGI technologies, services, and standards. Fellows will participate in hybrid bootcamps, receive on-demand business, technical and collaboration support services and mentorship in order to increase the impact of their collaborations, and participate in a pitch and award ceremony. A pilot action with Canada will also be set up to provide additional or reciprocal fellowships to expand or reinforce initiated NGI collaborations. NGI Enrichers therefore offers a unique and 360° approach offering optimal preparations, ideal onsite conditions and long-term effects with sustainable collaboration partnerships, and will specifically allow to (1) enhance EU-US and EU-Canada cooperation in the development of NGI technologies, services and standards, (2) reinforce and expand NGI transatlantic ecosystem of top researchers, high-tech startups / SMEs and Internet-related communities collaborating on the evolution of the Internet according to a human-centric approach (3) help sharing the EU vision and values with US and Canadian counterparts and thus (4) contribute to the EU internet policy objectives.

Keywords: next generation internet innovators decentralised technologies and solutions data sovereignty human centric approach ai 5g 6g internet of things could and edge computing xtended reality
Mechanism and functional consequences of Streptococcus pneumoniae chromatin remodeling of epithelial tissue (KDM6B-BACHROM)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-05-01
End date: 2027-04-30
Duration (months): 24.0
Total project cost (EUR): 226420.56
EU funding (EUR): 226420.56
Participants: 1
Project status: SIGNED

Streptococcus pneumoniae is a pathobiont that is a top 10 WHO priority pathogen. Whilst it is commonly carried in the nasal cavity of healthy populations, it also causes invasive disease in vulnerable populations causing pneumoniae, meningitis, and septicaemia. However, the host factors involved in maintaining colonisation or triggering an immune response are currently unknown, and my research project aims to address this knowledge gap. In line with the expertise of the Hamon lab, the project will focus on bacteria-induced histone modifications which corelate with altered host gene expression. Following on the discovery that a colonising and asymptomatic strain of S. pneumoniae activates the histone demethylase KDM6B for immune homeostasis, the project will characterise the KDM6B-mediated response at the molecular level in a physiological model of nasal epithelium. Specifically, the research objectives are to: 1) Identify KDM6B binding partners during S. pneumoniae challenge 2) Define the nasal tissue response to S. pneumoniae 3) Characterize the KDM6B-mediated nasal tissue response to the bacteria The host laboratory has a powerful model of reconstituted nasal epithelium model in which responses to a colonising or an invasive strain of S. pneumoniae can be evaluated. I will use and gain expertise in cutting edge techniques such as mass spectrometry to determine KDM6B binding partners and single-cell RNA sequencing along with spatial transcriptomic technology (MERFISH) to analyse host cell responses at the single cell level. The field of bacteria mediated histone modifications is in its infancy and offers a large margin of discovery. Altogether this project will advance our understanding of the signals and pathways that regulate the balance between homeostasis and infection and will identify and characterise original mechanisms of host chromatin-bacteria cross talk which could be targeted for therapeutic purposes.

Keywords: chromatin,histone methylation,s pneumoniae colonisation,
Strengthening the OAPEN infrastructure in support of European Union Open Access policy (OAPEN-EU)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Reforming and enhancing the European R&I System
Theme: Euratom
Destination: Euratom
Action type: Coordination and support actions
Countries involved: Netherlands
Call: Strengthening the OAPEN initiative in support of European Union Open Access policy (HORIZON-EURATOM-2025-OAPEN-IBA, 2025)
Start date: 2025-05-01
End date: 2027-04-30
Duration (months): 24.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: SIGNED

Monographs and other forms of academic books remain integral to scholarly output and the communication of research, particularly within the social sciences and humanities (SSH). Developing a culture of Open Science within the European Research Area (ERA), in alignment with the Council conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing (May 2023), must therefore encompass open access (OA) to scholarly books. In the Annotated Grant Agreement of the EU Funding Programme 2021-2027 this is clearly addressed: “The beneficiaries must ensure open access to peer-reviewed scientific publications relating to their results.” whereas the term ‘publications’ include both journal articles and books. This project directly addresses the EU’s Open Access policy requirements by strengthening the OAPEN Library, a critical infrastructure for curating, hosting, disseminating, and preserving peer-reviewed long-form publications, i.e. scholarly books (monographs, edited collections etc.) and book chapters. By enhancing services tailored to the specific needs of Horizon Europe-funded books, the project supports the open access mandates of the European Commission and the European Research Council under Horizon Europe and contributes to the EU’s broader Open Science framework.

Keywords: open access books,infrastructure,funder collections,monitoring,horizon europe